You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.

View the best savings account rates here

Julie Cooke Biography and Net Worth

Insider of Neurocrine Biosciences

Julie Cooke was appointed Chief Human Resources Officer in September 2017. She joined Neurocrine Biosciences from the Sanford Burnham Prebys Medical Research Institute where she served as Senior Vice President for Human Resources and was a member of the executive management team. Previously, Ms. Cooke held multiple positions at Life Technologies, including being the human resource partner to the Chief Operating Officer, Division Presidents and Global Function Leads. Prior to Life Technologies, she ran human resources and was a member of the executive management team at SGX Pharmaceuticals. Ms. Cooke began her career at PepsiCo., The Pepsi Bottling Group, and Gateway , where she held positions of increasing responsibility in human resources. She holds a B.A. in Economics from Colorado College.

What is Julie Cooke's net worth?: The estimated net worth of Julie Cooke is at least $2.30 million as of August 1st, 2024. Ms. Cooke owns 18,202 shares of Neurocrine Biosciences stock worth more than $2,301,825 as of December 3rd. This net worth estimate does not reflect any other investments that Ms. Cooke may own. Learn More about Julie Cooke's net worth.
How old is Julie Cooke?: Ms. Cooke is currently 58 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Julie Cooke's age.
How do I contact Julie Cooke?: The corporate mailing address for Ms. Cooke and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Julie Cooke's contact information.
Has Julie Cooke been buying or selling shares of Neurocrine Biosciences?: Julie Cooke has not been actively trading shares of Neurocrine Biosciences during the last quarter. Most recently, Julie Cooke sold 12,632 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $153.26, for a transaction totalling $1,935,980.32. Following the completion of the sale, the insider now directly owns 18,202 shares of the company's stock, valued at $2,789,638.52. Learn More on Julie Cooke's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 45 times. They sold a total of 574,605 shares worth more than $78,018,075.30. The most recent insider tranaction occured on August, 15th when Director William H Rastetter sold 14,250 shares worth more than $2,090,332.50. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 8/15/2024.

Julie Cooke Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2024	Sell	12,632	$153.26	$1,935,980.32	18,202
7/16/2024	Sell	900	$150.04	$135,036.00	18,202
7/1/2024	Sell	10,000	$140.19	$1,401,900.00	18,202
9/1/2023	Sell	824	$110.93	$91,406.32	17,263
5/1/2023	Sell	11,397	$103.89	$1,184,034.33	16,169
6/27/2022	Sell	754	$100.00	$75,400.00	16,918
10/4/2021	Sell	987	$101.73	$100,407.51
10/2/2020	Sell	987	$95.26	$94,021.62	9,549
10/2/2019	Sell	987	$88.56	$87,408.72

Julie Cooke Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $126.46

$125.41

$126.70

50 Day Range

MA: $119.42

$111.62

$127.91

2 Week Range

Now: $126.46

$110.95

$157.98

Volume

149,947 shs

Average Volume

870,869 shs

Market Capitalization

$12.80 billion

P/E Ratio

33.90

Dividend Yield

N/A

Beta

0.34

Your bank is lying to you.

From MyBankTracker | Ad